InvestorsHub Logo
Followers 64
Posts 5750
Boards Moderated 0
Alias Born 07/09/2003

Re: Triple9 post# 605

Monday, 02/27/2017 8:11:16 AM

Monday, February 27, 2017 8:11:16 AM

Post# of 859
This one is a sleeper. They have been building their business and waiting for their customers to receive approval of their procedures. They have been ahead of the curve on this and it has been expensive to get into this position.

The most recent outlook from the company was this:

Mike Rice, BioLife CEO, commented on the Company's performance by stating, "2016 was another strong year of execution that broadened the biopreservation media franchise we have built in the regenerative medicine market. Our efforts should be further rewarded in 2017 with possible customer regulatory approvals of their cell-based therapies. Customer adoption of the evo Smart Shipper and biologistex SaaS is anticipated this year and our recent JV restructuring was an important accomplishment to enable growth without BioLife having to raise additional capital."



https://finance.yahoo.com/news/biolife-solutions-announces-2016-revenue-110000452.html

techisbest

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLFS News